engleski

The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

This is a retrospective analysis of the frequency of CNS relapses in DLBCL patients treated prior to and during the rituximab era. The addition of rituximab to chemotherapy significantly decreases the frequency of CNS relapses.

antibodies monoclonal murine derived; antineoplastic combined chemotherapy protocols; central nervous system neoplasms; lymphoma large B-cell diffuse

nije evidentirano